POONGJEON PHARMACY CO.,LTD.
Founded 2014, KOSDAQ-listed 2020, Poongjeon Pharmacy develops stem cell therapies, sells Iroro/Dermassimo cosmetics, runs pharma wholesale.
Price
Change
Market cap
Business overview
Source: DART corporate disclosurePoongjeon Pharmacy was founded in 2014 and listed on KOSDAQ as a technology growth company in June 2020. It develops stem cell therapeutics SCM-CGH and SCM-AGH via its subfractionation culturing method, sells hair and skin products under the Iroro and Dermassimo brands, and runs a pharmaceutical wholesale business. It holds a clinical-approval and exclusive-distribution agreement with Malaysia's Duopharma Biotech Berhad covering Malaysia, Singapore, Brunei and the Philippines, absorbed Dermassimo Co., Ltd. on November 25, 2025, and supplies prescription drugs to hospitals such as Chung-Ang University Hospital and Gangnam Severance Hospital and via Public Procurement Service tenders.
Products & technology
- Iroro Dearscalp hair productsMen's and women's shampoo, treatment, tonic, and serum using stem cell culture medium (CXCL1)
- Iroro Nuvon skin productsMulti serum, body lotion, and AD intensive cream using stem cell culture medium for skin soothing
- DermassimoHair-loss relief ampoule and men's/women's shampoo using Redensyl ingredient
- Prescription drug wholesale supplySupply of prescription drugs and narcotics (pain management) to major hospitals and via Public Procurement Service tenders
R&D and key agreements
Source: DART corporate disclosureSCM-CGH · 만성 이식편대숙주질환 · Stem cell therapeutic based on subfractionation culturing method
SCM-AGH · 중등증-중증 급성 췌장염 · Stem cell therapeutic based on subfractionation culturing method
SCM-AGH · 중등증-중증 아토피 피부염 · Stem cell therapeutic based on subfractionation culturing method
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition